[2] As a sexual dysfunction agent, melanotan II was licensed by Competitive Technologies to Palatin Technologies
Robust outcome data, including the landmark SELECT trial (encompassing over 17,600 participants) and the SUSTAIN-6 trial (3,297 participants), confirmed a statistically significant and clinically meaningful reduction in MACE (Major Adverse Cardiovascular Events) incidence for those treated with semaglutide compared to placebo, showing superior protection in patients with obesity/overweight and established CV disease
For more detail on missed-dose timing, this GLP-1 missed dose guide walks through the weekly window and what to do next
Some people say there is no fun in their life because theres no one to have fun with, you know, the lonely people out there
Our team will be available to address any concerns and help manage side effects